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PU.1 is not strictly required for B cell 
development and its absence induces 
a B-2 to B-1 cell switch
 
Min Ye, Olga Ermakova, and Thomas Graf
 
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461
 
In this paper, we describe the unexpected outgrowth of B lineage cells from PU.1
 
 
 
/
 
 
 
 fetal 
liver cultures. The cells express all early B cell genes tested, including the putative PU.1 
target genes IL-7R and EBF but not B220, and can produce immunoglobulin M. However, 
we observed a delay in the PU.1
 
 
 
/
 
 
 
 B cell outgrowth and reduced precursor frequencies, 
indicating that although PU.1 is not strictly required for B cell commitment, it facilitates B 
cell development. We also ablated PU.1 in CD19-expressing B lineage cells in vivo, using a 
Cre-lox approach that allows them to be tracked. PU.1 excision resulted in a shift from B-2 
cells to B-1–like cells, which dramatically increased with the age of the mice. Our data 
indicate that this shift is predominantly caused by a B-2 to B-1 cell reprogramming. 
Furthermore, we found that B-2 cells express substantially more PU.1 than B-1 cells, which 
is consistent with the idea that maintenance of the B-2 cell phenotype requires relatively 
high levels of PU.1, but B-1 cells require little.
 
Mice lacking PU.1 contain neither B cells nor
myelomonocytic cells and fetal liver suspen-
sions neither generate B cells nor macrophages
in culture (1–3), although immature myeloid
cell lines can be established in the presence of
IL-3, IL-6, and stem cell factor (SCF) (4). Failure
to produce B lineage cells in culture can be
rescued by putative downstream target genes:
enforced expression of the EBF transcription
factor led to B cell outgrowth within 4–6 d,
and of IL-7R within 10–14 d and at low fre-
quencies. The cells exhibit immunoglobulin
rearrangements and are CD45/B220 antigen
negative (5, 6). These observations, together
with evidence indicating that PU.1 directly regu-
lates the IL-7R (5) and EBF genes (7), led to the
conclusion that PU.1 is required for the commit-
ment of B lineage cells. However, the exact
point in development where PU.1 is required is
poorly understood. One study described the
virtual absence of HSCs (Lin
 
 
 
Sca-1
 
 
 
Kit
 
 
 
 cells)
in PU.1
 
 
 
/
 
 
 
 fetal liver (8), but another one re-
ported the absence of early B cell precursors
(IL-7R
 
 
 
Kit
 
 
 
 cells) (7). It also remains unknown
whether PU.1 plays a role at later stages of B
cell differentiation, where the gene is also ex-
pressed (9).
 There are three main subpopulations of B
cells in mice and humans: B-1, B-2 (also called
follicular), and marginal zone B (MZB) cells.
B-1 cells, which exist as B-1a (CD5
 
 
 
) and B-1b
(CD5
 
 
 
) variants, are mostly present in the
peritoneum where they are maintained by self-
renewal. B-1a cells and part of B-1b cells are
thought to be of fetal origin (10). In contrast,
B-2 cells reside in follicles of secondary lym-
phoid organs and are replenished from precur-
sors formed in the bone marrow (11). Finally,
MZB cells are localized in the marginal zones
of splenic follicles and are thought to be recruited
from mature B-2 cells (12). Whereas B-2 and
MZB cells express B220 antigen, B-1 cells are
B220
 
neg/low
 
 and express CD43. In addition, the
three B cell subsets can be distinguished by the
expression of IgM, IgD, CD21, and CD23 cell
surface antigens.
Whether B-1 cells represent a lineage distinct
from B-2 cells remains controversial (13). The
ratio of B-1 and B-2 lineage cells can be dramati-
cally altered by both loss and gain of function
experiments. Thus, mice lacking molecules
necessary for the initiation of B cell receptor
signaling show a loss of B-1 lineage cells and
mice expressing specific B cell receptor (BCR)
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transgenes show an expansion of the B-2 cell compartment
(14). Interestingly, BCR signaling strength determines the
ratio between the two cell compartments: in BCR-deficient
mice transgenic for LMP2, a BCR surrogate, high LMP2
levels induce the expansion of B-1 type cells whereas low
levels promote the formation of B-2 and MZB cells (15). To
interpret these results, two explanations were offered. First
that B-1 and B-2 cells represent two distinct lineages, where
low BCR signaling drives the progression of B-2 progenitors
and high signaling drives B-1 cell progression. And second,
that the strength of BCR signaling determines which of the
two B cell subtypes is specified from a “B-0” cell.
In this paper, we describe the unexpected outgrowth of
B lineage cells in culture from PU.1
 
 
 
/
 
 
 
 fetal liver. These
cells share several markers with B-1 cells. In addition, in vivo
deletion of PU.1 in CD19-expressing B lineage cells showed
the presence of cells resembling B-1 cells and the concomi-
tant loss of B-2 cells, which is an effect that was more pro-
nounced in older mice. Our data indicate that this imbalance
is caused by a B-2 to B-1 cell reprogramming. The detection
of the complex alterations caused by PU.1 ablation in vivo
was greatly facilitated by a genetic approach that allowed
tracking of individual cells containing the deletion.
 
RESULTS
PU.1-defective fetal liver cultures give rise to B lineage cells 
 
To analyze the role of PU.1 in B cell development we used a
recently developed mouse line in which exons 4 and 5, en-
coding the DNA binding and PEST domains, are flanked by
loxP sites. Crossing these mice with a 
 
 
 
-actin–Cre line re-
sulted in mice with a germline excision of PU.1 (Fig. 1
A). The homozygous animals produce no detectable PU.1
mRNA, die soon after birth, and their fetal livers contained
no detectable Mac-1
 
 
 
Gr1
 
 
 
 myelomonocytic cells or B220
 
 
 
CD19
 
 
 
 B cells (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20051089/DC1). PU.1
 
 
 
/
 
 
 
 liver cell
suspensions that were seeded under conditions permissive
for both B and myeloid cell growth (S17 stroma cells con-
taining IL-3, IL-7, SCF, and Flt-3L) developed into foci of
small round, refractile cells within 2–3 wk from all 21 fetal
livers (embryonic day [E] 14.5–18.5) tested (Fig. 1 B). The
cultures could be split every 3–4 d, proliferating slightly
faster than WT cells, and grew for 
 
 
 
6 mo without a de-
tectable crisis. These cells expressed CD19, CD43, CD24
(HSA), and BP1, but not B220 and CD45 antigens. They
were also negative for erythroid (Ter119), T cell (Thy-1,
CD3, CD4, and CD8), NK cell (NK1.1) and myelomono-
cytic (Mac-1, Gr1, and F4/80) surface markers (Fig. 1 C and
not depicted). Thus, the cultured PU.1
 
 
 
/
 
 
 
 cells resemble
pro/pre–B cells and also share characteristics with B-1 cells
(B220
 
neg/low
 
CD43
 
 
 
CD19
 
 
 
). Next, we compared the gene
expression profiles (RT-PCR) of freshly isolated fetal liver
with cultured derivatives. As can be seen in the left panel of
Fig. 1 D, E15.5 PU.1
 
 
 
/
 
 
 
 fetal liver cells expressed no B cell
specific genes, except E2A (E47). In contrast, cultured
PU.1
 
 
 
/
 
 
 
 B lineage cells expressed all B cell–specific genes
tested, including EBF and Pax-5 as well as their target genes
RAG1, IL-7R, 
 
 
 
5, and V–pre-B, indicating that cultures
derived from PU.1
 
 
 
/
 
 
 
 fetal liver correspond to bona fide B
lineage cells. We further tested whether these PU.1
 
 
 
/
 
 
 
 B
cells expressed other lineage genes. As shown in the right
panel of Fig. 1 D, they were negative for the myeloid genes
c-fms (CSF-1R), lysozyme, MPO, and the erythroid genes
GATA-1 and 
 
 
 
-globin. However, although the cultured
PU.1
 
 
 
/
 
 
 
 cells did not express the T cell genes GATA-3 or
pre-T
 
 
 
 (unpublished data), they expressed lck and ZAP-70,
Figure 1. Establishment of B cell cultures from PU.1-deficient fetal 
liver. (A) Strategy to generate PU.1 germline deletion mice. (B) Schematic of 
the cell culture system and micrograph of an E14.5 PU.1 /  fetal liver–
derived colony growing out after 14 d. (C) FACS analysis of the cultured cells. 
Numbers in quadrants, set by staining with appropriate isotype controls, 
represent percentage of cells. (D) RT-PCR analysis of freshly isolated PU.1 /  
and control E15.5 fetal liver cells or the knockout cells after culturing.  
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genes that are normally expressed in T and NK cells and
whose products play important roles in TCR signaling. Lck
is also expressed in B-1 cells where it regulates BCR signal-
ing transduction (16). Together with the pattern of cell sur-
face antigens detected by FACS on PU.1
 
 
 
/
 
 
 
 cells, the gene
expression profile suggests that cultured B lineage cells from
PU.1
 
 
 
/
 
 
 
 fetal liver resemble B-1 cells.
 
PU.1-defective B cells contain immunoglobulin 
rearrangements and can express IgM
 
To examine PU.1
 
 
 
/
 
 
 
 fetal liver derived cell cultures for im-
munoglobulin heavy chain rearrangements by PCR, a series
of 5
 
 
 
 primers specific to different V or D region families
were used together with a 3
 
 
 
 primer downstream of JH4
(17). Multiple heavy chain DJ and VDJ rearrangements indi-
cated by different sizes of PCR products were found in cul-
tured PU.1
 
 
 
/
 
 
 
 fetal liver cells (Fig. 2 A and Table I), but
none were detected in freshly isolated PU.1
 
 
 
/
 
 
 
 fetal livers
(not depicted). Joining of V to D region sequences was seen
with both proximal (VH7183) and distal V family genes
(VHJ558) within the 21 VDJ rearrangements sequenced
(Table I). This suggests that the lack of PU.1 does not pre-
vent a “contraction” of the heavy chain locus as has been de-
scribed for pro–B cells lacking Pax5 (18). Out of the 11
PU.1
 
 
 
/
 
 
 
 B cell lines analyzed, 4 were found to contain low
proportions of IgM-positive cells (Fig. 2 B), whereas 7 were
negative. To determine whether the negative cells can up-
regulate IgM expression, one line was grown in the absence
of IL-7 and found to become IgM
 
 
 
 (Fig. 2 C). Therefore,
cultured PU.1
 
 
 
/
 
 
 
 fetal liver derived B cells exhibit heavy
chain DJ and VDJ rearrangements and can produce IgM.
 
PU.1
 
 
 
/
 
 
 
 fetal livers contain fewer B cell precursors, 
and these are delayed in their outgrowth 
 
To analyze the frequency of B lineage progenitors in PU.1
 
 
 
/
 
 
 
fetal livers, we performed a limiting dilution analysis. Lin
 
 
 
/low
 
Sca-1
 
 
 
c-Kit
 
 
 
 (LSK) cells were sorted from fetal livers of
E16.5 PU.1
 
 
 
/
 
 
 
 embryos, with a pool of similarly sorted
PU.1
 
 
 
/
 
 
 
 (het) and WT embryos serving as positive controls.
The two cell samples were then placed at increasing cell
numbers in wells containing S17 stroma cells plus cytokines
and colonies scored between 4 and 22 d. B cell colonies
were identified by morphology and confirmed by CD19 an-
tibody staining. The LSK cells from PU.1
 
 
 
/
 
 
 
 fetal livers
were found to generate 
 
 
 
25 times fewer B cell colonies than
the WT/het controls (Fig. 3 A). In addition, the formation
of B cell colonies was delayed compared with the controls
(Fig. 3 B). These data show that PU.1
 
 
 
/
 
 
 
 fetal livers contain
a reduced number of B cell progenitors compared with con-
trols and that those that are present show a delayed develop-
ment into B lineage cells.
 
In vivo inactivation of PU.1 in CD19
 
 
 
 cells leads to 
a decrease of B cells in the bone marrow
 
To determine the role of PU.1 in B cell development in
vivo, we crossed the PU.1 conditional knockout mice with a
strain that expresses Cre-recombinase under the control of
the endogenous CD19 locus (19). To monitor the deletion
frequency of PU.1, these mice were then crossed with
ROSA26-EYFP reporter mice, in which removal of a LoxP-
flanked stop cassette irreversibly activates EYFP expression.
The conditional knockout mice have the genotype PU.1
 
 
 
/loxP
 
CD19Cre
 
 
 
/ki
 
ROSA26-EYFP
 
 
 
/ki
 
 whereas the control mice
are PU.1
 
 
 
/loxP
 
CD19Cre
 
 
 
/ki
 
ROSA26-EYFP
 
 
 
/ki
 
, which cor-
responds in their deleted forms to PU.1 homozygous and het-
erozygous mice, respectively (Fig. 4 A and Fig. S2 [available at
Figure 2. Immunoglobulin rearrangements and IgM expression in 
cultured PU.1 /  fetal liver cells. (A) Heavy chain (IgH) VDJ rearrange-
ment detected by the use of 7 VH family consensus primers and one JH 
consensus primer (lanes A–G). Asterisks indicate VDJ bands whose nature 
was confirmed by sequencing (Table I). (B) Surface IgM expression on 
PU.1 /  clone E18-6.1 (gray shading) compared with isotype control (bold 
line). (C) PU.1 /  clone E18-6.2 grown in the absence of IL-7 for 7 d (gray 
shading) compared with isotype control (bold line).
 
Table I.
 
Immunoglobulin heavy chain DJ and VDJ 
rearrangements in PU.1
 
 
 
/
 
 
 
 fetal liver–derived B cells
 
5
 
 
 
 primer
(corresponding
families)
No. of 
clones
sequenced
No. of
unique
clones
No. of clones
with in-frame
rearrangements
 
Fetal liver DJ D
 
H
 
Q52 (DHQ52) 5 2 1
DSF(D
 
H
 
FL16; 
D
 
H
 
SP2) 13 4 1
Fetal liver VDJ V
 
H
 
A (V
 
H
 
J558) 4 2 2
V
 
H
 
B (V
 
H
 
Q52) 5 2 2
V
 
H
 
E (V
 
H
 
7183;
V
 
H
 
DNA4) 9 4 0
V
 
H
 
F (V
 
H
 
J606; 
V
 
H
 
S107;
V
 
H
 
X24) 3 3 0 
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http://www.jem.org/cgi/content/full/jem.20051089/DC1]).
PCR analysis of PU.1 DNA in B cells showed that there was
an excellent correlation between the activation of EYFP and
PU.1 deletion (Fig. 4 B). As shown in Fig. 4 C, the propor-
tion of CD19
 
 
 
 B cells in the bone marrow of the knockout
mice was reduced compared with the control group. To ex-
amine whether deletion of PU.1 caused a selective loss of
early progenitors, we determined the proportion of EYFP
 
 
 
cells in pro/pre–B cells (CD19
 
 
 
IgM
 
 
 
) and in immature B
cells (CD19
 
 
 
IgM
 
 
 
). As illustrated in Fig. 4 (C and D), com-
pared with controls, these values were 
 
 
 
50% lower for pro/
pre–B cells in the knockout mice, 
 
 
 
20% lower for immature
B cells, and essentially unchanged for B220
 
 
 
CD19
 
 
 
IgD
 
 
 
 ma-
ture B cells in the spleen and blood. This indicates that early B
cell precursors are selectively lost after PU.1 ablation, proba-
bly because they acquire a B-1–like phenotype and leave the
bone marrow (see Discussion).
 
Ablation of PU.1 induces an age-dependent formation of 
B220
 
low
 
CD43
 
  cells in the bone marrow, spleen, and blood 
As shown in Fig. 5 A, B220low EYFP  cells were detected in
the bone marrow, spleen and blood of the conditional PU.1
knockout mice, and these cells also expressed high levels
of CD43. Such cells were not seen in control mice
(B220lowEYFP  cells in the spleen represent plasma cells
since they are CD19 CD138 EYFPbright, whereas B220low
EYFP  cells from knockouts are CD19 CD138 EYFP ;
Fig. 5 A and not depicted). Among the EYFP  cells with the
PU.1 deletion, the expression of B220 varied between the
three tissues. Although B220 expression was down-regulated
29.0   3.8-fold in the spleen and 38.1   8.9-fold in the
blood, there was only a 12.0   0.6-fold decrease in the bone
marrow. Surprisingly, CD45 was only slightly down-regu-
lated in the B220lowEYFP  cells from spleen and blood
(1.6   0.3 in spleen and 1.6   0.2 in blood; five knockout
mice, 6 mo old) without showing changes in the bone mar-
row. In addition, as shown in Fig. 5 (B and C), the propor-
tion of B220lowEYFP  cells in the knockouts increased with
the age of the mice. As shown in Fig. 5 B, the analysis of pe-
ripheral blood of a single mouse over time showed an eight-
fold increase of B220lowEYFP  cells. In summary, mice with
a B cell–specific PU.1 knockout contain CD19  cells that
are B220lowCD43 , resembling the PU.1 /  fetal liver–
derived B lineage cells. These B-1–like cells increased in
number over time.
PU.1 conditional knockouts exhibit an increased ratio of 
B-1/B-2 cells in the spleen
To analyze the effect of PU.1 deletion in B-2, B-1, and
MZB cell subsets, we tested the distribution of cells express-
ing CD23 and CD21 antigens within the CD19  B cell
population of the spleen from the control and knockout
mice. As shown in Fig. 6 (A and B), the distribution of the
B-2 cell subset (CD23 CD21 ), B-1/transitional B subset
(CD23lowCD21low), and the MZB subset (CD23 CD21high)
varied between the two mouse strains. Whereas 6-mo-old
controls contained about threefold more B-2 cells than B-1/
transitional B cells (3.0   0.8, four mice, 6 mo old), knock-
out mice contained about twofold more B-1 than B-2 cells
(2.1   0.5, five knockout mice, 6 mo old; B-1 cells were
distinguished from transitional B cells by the expression of
CD43 and lack of B220 expression; Figs. 5 A and 6 B). In
contrast, the proportion of MZB cells, although highly vari-
able between mice, did not differ substantially between the
two groups. However, the knockout MZB cells exhibited a
small but notable decrease in the expression of CD21 (1.5  
0.2, four control mice and five knockout, 6 mo old). The
increase of B-1–like cells became more dramatic with age:
nearly all B cells of a 14-mo-old conditional knockout were
CD23lowCD21low and both the B-2 and MZB subsets had
disappeared. The analysis of spleen sections from 6-mo-old
littermates revealed that the B220lowEYFP  (knockout) cells
localized to the follicular region (Fig. 6 C). In contrast, in a
14-mo-old knockout, the spleen structure was completely
Figure 3. Frequency and outgrowth kinetics of PU.1 /  fetal liver B 
cells. LSK cells were sorted from E16.5 PU.1 /  as well as a mixture of PU.1 /  
with PU.1 /  fetal liver cells and plated in 96-well plates containing S17 cells 
plus cytokines. Formation of B cell colonies, consisting of  10 cells, was 
scored between 4 and 22 d of culturing. (A) Percentage of wells with no 
colonies scored at day 22 relative to cell number seeded. (B) Percentage of 
large colonies (consisting of  100 cells) scored at different days of culture.JEM VOL. 202, November 21, 2005 1415
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disturbed and B220lowEYFP  cells were dispersed through-
out the whole spleen (Fig. 6 D). Additional criteria to distin-
guish B-2 cells from B-1 cells are IgD/IgM expression and
size. As shown in Fig. 6 (E and F), CD19  B cells from the
14-mo-old knockout exhibited high IgM and low IgD ex-
pression and were larger in size than control B-2 cells, thus
resembling B-1 cells. Whereas the splenic B cell architec-
ture was disrupted, the total CD19  cell number, although
highly variable between mice, showed no notable difference
between the two groups (Fig. 6 G). Together, our results in-
dicate that the in vivo deletion of PU.1 in the B cell lineage
induced a gradual shift of B-2 cells toward B-1–like cells,
which eventually led to an altered structure of the spleen.
B-1 cells replace B-2 cells in the peritoneum of PU.1 
conditional knockout mice
Another dramatic change in the distribution of cells within
the B cell subsets was observed within the peritoneal cavity.
As shown in Fig. 7 A, even fairly young (6 mo old) condi-
tional PU.1 knockout mice contained essentially only B-1
Figure 4. Conditional in vivo PU.1 ablation strategy and analysis of 
B cells in the bone marrow. (A) Strategy of generating B cell–specific PU.1 
knockout mice, and how EYFP expression tracks Cre activity in individual cells. 
(B) PCR analysis of floxed PU.1 allele deletion in PU.1 conditional knockout 
mice. DNA was extracted from sorted splenic B cells (CD19 EYFP B220  cells 
from PU.1 /loxP control mice; CD19 EYFP B220  and CD19 EYFP B220low 
cells from PU.1 /loxP knockout mice) as well as Mac-1  macrophages (M ) 
from both groups and amplified with the primer combination 1/2/3. Primer 
combination 1/2 shows amplification of the WT ( ) and floxed PU.1 alleles 
(LoxP) as different sized bands; primers 1/3 show the deleted allele ( ). 
Detection of Crewas used as a control for DNA input. (C) FACS analysis of 
bone marrow cells from a control and a conditional knockout mouse. 
CD19 IgM  cells, corresponding to pro/pre–B cells, and CD19 IgM  cells, 
corresponding to immature cells were gated and the proportion of EYFP  
cells (representing the fraction of cells with active Cre recombinase) shown 
below. The numbers indicate percentage of cells in the corresponding 
quadrants. (D) Histogram summarizing the results obtained with pro/pre–B 
and immature B cells from bone marrow and with mature B-2 cells 
(B220 CD19 IgD ) from spleen and blood. Error bars represent means   
standard deviations. The numbers of mice analyzed are indicated.PU.1 IN B-1 AND B-2 CELL DEVELOPMENT | Ye et al. 1416
Figure 5. B cells with an altered phenotype can be detected in 
conditional PU.1 knockout mice and increase with the age. (A) FACS 
plots of the bone marrow, spleen, and blood leukocytes in a control and a 
conditional knockout mouse at 6 mo old. The plots show B220 versus EYFP 
expression. Arrows indicate the EYFPbright plasma cells in the control and 
the knockout spleen. Histograms show levels of CD43 expression of EYFP  
cells within the gates indicated in green for B220  control cells; in blue 
for B220  knockout cells; and in red for B220low knockout cells. (B) FACS 
plots of the peripheral blood of PU.1 knockout mouse 25 at 1, 5, 9, and 
12 mo old. (C) Histogram summarizing the proportion of B220lowEYFP  
cells in EYFP  B cell population within the peripheral blood in control 
(white bars) and knockout mice (black bars) at different age. Error bars 
represent means   standard deviations. The numbers of mice analyzed 
are indicated.
cells (B220neg/low) but no B-2 cells (B220high), whereas con-
trol mice contained similar proportions of B-1 and B-2
cells. To eliminate the possibility that the PU.1 /  B-1 cells
observed represent B-2 cells that simply have down-regu-
lated B220, we measured their forward and sideward scatter
properties as well as their IgM/IgD expression. As shown inJEM VOL. 202, November 21, 2005 1417
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Fig. 7 (B and C), they resembled control B-1 cells in size,
granularity, and IgM expression. However, they expressed
lower levels of IgD and were negative for Mac-1 and CD5
expression (not depicted). In spite of the virtual disappear-
ance of the B-2 cell compartment in the peritoneum of the
conditional knockouts (Fig. 7 D), the numbers of CD19 
Figure 6. Analysis of B cell subsets in the spleen of 6- and 
14-mo-old mice. (A and B) Distribution of B-1, B-2, and MZB cells in 
6-mo and 14-mo-old control and knockout littermates, with numbers 
indicating the percentages in the corresponding gates (pink circles). The 
splenocytes were isolated and analyzed by FACS, after gating on CD19 
positive cells. (C and D) Immunofluorescence analysis of splenic cryosections 
from the same mice analyzed in A and B. Sections were stained with 
PE-coupled B220. EYFP expression tracks B cells in which Cre has excised 
both PU.1 and the stop cassette of the reporter. The primary follicles are 
circled with dashed white lines, and EYFP B220low cells in the knockout 
are indicated by arrows. Original magnification, 10. (E) FACS plots of 
the CD19  splenocytes from the 14-mo-old control and knockout 
littermates. The plots show B220 versus CD43, IgM, and IgD expression, 
respectively; the histograms show levels of CD43, IgM, and IgD expression 
in CD19  cells from the control (blue) and the knockout (red). (F) Histo-
grams of forward (FSC) scatter distribution of CD19  cells from the 
control (blue) and the knockout (red). (G) Absolute number of CD19  B 
cells in spleen of control (white bar, n   7, 6–9 mo old) and knockout 
mice (black bar, n   10, 6–9 mo old). Error bars represent means   
standard deviations.PU.1 IN B-1 AND B-2 CELL DEVELOPMENT | Ye et al. 1418
cells were comparable with those of WT mice (Fig. 7 E). It
is not likely that this was caused by the death of B-2 cells,
because we did not see an increase of dead cells in CD19 
population in spleen peritoneum, as measured by DAPI
staining. To investigate the possibility that the B-2/B-1 im-
balance was caused by an enhanced proliferation of B-1
cells, we sorted B-1 and B-2 cells from WT mice, as well as
B-1–like cells from knockouts and placed them in culture
(without stroma or added cytokines) for 2 d. A thymidine
incorporation assay that cultured the cells for 2 d and la-
beled for 12 h showed no notable differences between the
knockout and control cells (Fig. 7 F). We also measured
proliferation responses of the cells to LPS. As shown in Fig.
7 G, the thymidine incorporation values of knockout B-1–
like cells (and to a lesser extent of control B-1 cells) were
increased after LPS treatment, whereas those of B-2 cells
isolated from the peritoneal cavity remained unchanged. In
summary, conditional inactivation of PU.1 causes an in-
crease of cells resembling B-1b cells in the peritoneum at
the expense of B-2 cells. Short-term ex vivo culture assays
suggest that this imbalance was not the result of an increased
proliferation capacity of B-1 cells lacking PU.1.
Deletion of PU.1 in B cell precursors induces the gradual 
down-regulation of B220 expression 
The observed B-2/B-1 cell imbalance in conditional PU.1
knockout mice suggested the possibility that the deletion of
PU.1 in B2 cells causes them to become B-1–like cells. This
implies that B-1 cells require less PU.1 for their formation
and maintenance. To test this possibility, we performed a
semi-quantitative RT-PCR analysis of peritoneal B-1 and
B-2 cells and the PCR products were quantified. As shown
in Fig. 8 A, B-2 cells from a WT animal have about eight-
fold higher levels of PU.1 than B-1 cells, although B-1 cells
were not negative. To directly test whether B-2 cells can be
induced to switch to become B-1 cells when PU.1 is inacti-
vated, we isolated CD19  cells from the bone marrow of
PU.1 /loxPROSA26-EYFP /  mice and placed them in cul-
ture under conditions supporting pro/pre–B cell develop-
ment (S17 stroma plus cytokines). The cells were then incu-
bated with nuclear localized Cre recombinase protein fused
to TAT (20). Induction of EYFP expression in these cultures
indicated cells in which PU.1 became deleted. When the
cultures were analyzed 9, 14, and 40 d later, the EYFP  cells
were found to gradually down-regulate B220 expression, a
process resembling the slow reprogramming of B-2 cells in
vivo. In addition, there was a selective increase in the pro-
portion of EYFP  cells without appreciable induction of cell
death, suggesting that the PU.1 knockout cells proliferate
more rapidly under these culture conditions (Fig. 8 B).
CD43 could not be used as an additional marker to monitor
phenotypic changes because the culture conditions used fa-
vor the growth of CD43  pro–B cells. Together, these ob-
servations are consistent with the possibility that deletion of
PU.1 induces the reprogramming of B cell progenitors into
B-1–like cells.
Figure 7. Enrichment of B-1–like cells in the peritoneal cavity of 
conditional knockout mice. (A) FACS plots of CD19  peritoneal cells in 
6-mo-old control and knockout littermates, showing B-2 and B-1 cells and 
percentage of cells present in each quadrant. (B) Forward (FSC) and side 
(SSC) scatter distribution of cells within the gates indicated in the plots 
(green, control B-2 cells; blue, control B-1 cells; red, knockout B-1 cells). 
(C) B220 expression versus IgM, IgD, and Mac-1 expression, respectively, in 
CD19  peritoneal cells. The B-1 and B-2 subsets are indicated, with number 
in parentheses representing percentage of cells in the corresponding gate 
(circles). Histograms show levels of IgM, IgD, and Mac-1 expression of cells 
within the gates indicated in the plots. (D) Histogram summarizing the 
proportion of B-1 and B-2 cells within the peritoneal B cell population in 
control (white bars, n   4, 6 mo old) and knockout mice (black bars, n   5, 
6 mo old) with mean values and standard deviation. (E) Absolute number of 
CD19  B cells in the peritoneal cavity of controls (white bar, n   4, 6 mo old) 
and knockouts (black bar, n   5, 6 mo old). Error bars represent means   
standard deviations. (F) The proliferation capacity of peritoneal B subsets in 
vitro without stimulation. B cell subsets were sorted from the peritoneal 
wash from two 6-mo-old control mice and knockouts and placed in culture 
for 2 d. DNA synthesis was quantified by measuring [3H]thymidine incorpo-
ration. (G) Effect of the stimulation of LPS on the proliferation capacity of 
peritoneal B cells in vitro. (F and G) Control B-2 cells, control B-1 cells, and 
knockout B-1 cells are represented by white, gray, and black bars, respectively. 
Data are representative of two experiments performed in triplicate. JEM VOL. 202, November 21, 2005 1419
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DISCUSSION
Lineage specification and commitment in the absence of 
PU.1: implications for models of B cell development
Contrary to what was expected from the literature, we found
that B lineage cells can develop in the absence of PU.1 when
knockout fetal liver cell suspensions are placed in culture.
The cells express all early B cell genes tested (except CD45/
B220), contain immunoglobulin gene rearrangements, and
can produce IgM. Previous articles had described that no B
lineage cells can be grown from PU.1 /  fetal liver, unless
IL-7R or EBF was expressed in these cells (5, 7). This appar-
ent discrepancy does not reflect differences between different
PU.1 mutant alleles since our observations were reproduced
with a well-characterized knockout line (Singh, H., personal
communication). The explanation therefore is that because of
the extended latency of outgrowth of PU.1 /  B cells com-
pared with WT cells, exceeding the times at which such
cultures are traditionally kept, they had previously been over-
looked. We do not think that the growth of the PU.1-
defective cells is caused by spontaneous mutations that acti-
vate the expression of the IL-7R or EBF genes. Thus, the
frequency of outgrowths observed (PU.1 /  B cells were ob-
tained from all 21 PU.1 /  fetal livers tested within a time
frame of 2–3 wk, with  5 colonies per fetal liver) cannot be
explained by the known mammalian mutation rates of 10 7–
10 9 (for review see reference 21).
Our in vitro experiments indicate that the transcription
factor network that establishes and maintains B cell fate has a
built in robustness that permits it to assemble and perform
even in the absence of a major player. At the same time they
suggest that PU.1 facilitates commitment by rapidly activat-
ing downstream target genes such as EBF and IL-7R. A
somewhat similar situation applies to T cell development:
here PU.1 is also not strictly required but acts as a facilitator,
as T cells develop at low frequencies and delayed appear-
ance in PU.1 /  mice in vivo and in vitro (2, 22, 23).
That PU.1-defective B cells do not inappropriately express
erythro/myeloid cell restricted genes and cannot be induced
to differentiate into macrophages in the absence of IL-7 dif-
fers from findings with B lineage cells lacking other tran-
scription factors required for B cell development. Pro–B cells
that are defective for either Pax5 or E2A contain IgH DJ re-
arrangements, yet inappropriately express myeloid- and T
cell–restricted genes and can be induced to differentiate into
several myeloid lineages, as well as T cells and NK cells (24,
25). However, although PU.1 /  B cells do not become T
cells on OP9-DL1 stroma cells (reference 26; unpublished
data), it is striking that they express lck and ZAP-70, which
are genes that are normally expressed in normal T and NK
cells. In addition, ZAP-70 is expressed in an aggressive sub-
set of B cell chronic lymphocytic leukemia (27). It will be
interesting to determine whether these leukemic cells lack
PU.1 expression; and if so, whether the ablation of PU.1 is a
causative factor in their formation. 
PU.1 as a transcriptional regulator of B cell genes
The observation that B lineage cells express IL-7R and EBF
genes in the absence of PU.1 implies that the factor is dis-
pensable for their regulation. It is not likely that this is be-
cause of a redundancy with the closely related transcription
factor Spi-B since the outgrowth of PU.1 / B lineage cells
was observed even when Spi-B was absent (Singh, H., per-
sonal communication). Similarly, IL-7R has been shown to
induce the outgrowth of B cells from PU.1 / Spi-B /  fetal
liver (12). Therefore, although PU.1 is not required for the
expression of the IL-7R and EBF genes, it probably en-
hances their initial up-regulation in collaboration with other
transcription factors, such as E2A (28). A different mecha-
nism applies to the regulation of the PU.1 target gene CD45
(29). Although this gene is not expressed in fetal liver-
derived PU.1 /  B cells, it is expressed in B220lowEYFP  B
cells from PU.1 conditional knockout mice (unpublished
data). This suggests that the de novo expression of CD45,
but not its maintenance, requires PU.1; this is a situation that
is reminiscent of T cells, which express CD45 even after
they have down-regulated PU.1 (30). It also raises the possi-
Figure 8. PU.1 expression in peritoneal B cells and the effect of 
PU.1 ablation. (A) RT-PCR analysis of PU.1 expression in sorted WT B-2 
(B220hiCD19 IgMlo) and B-1 cells (B220low/negCD19 IgMhi). (B) Effect of 
PU.1 ablation on the phenotype and growth of B progenitor cells in vitro. 
CD19  cells were isolated from the bone marrow of a PU.1 /loxP   
ROSA26-EYFP /ki mouse, treated with soluble Cre-TAT protein, and were 
seeded on S17 stroma. The FACS plots show cells analyzed 9, 14, and 40 d 
later for the expression of B220 and EYFP. The numbers indicate the 
percentages of cells in the corresponding quadrants.PU.1 IN B-1 AND B-2 CELL DEVELOPMENT | Ye et al. 1420
bility that PU.1 is involved in the regulation of B220 ex-
pression at more than one level. B220 corresponds to a gly-
cosylated full-length CD45 molecule, which contains a
carbohydrate epitope recognized by the RA3-6B2 antibody
(the clone used for B220 detection) (31, 32). Thus, the ob-
served difference between CD45 and B220 expression in
EYFP  B cells from PU.1 knockouts raises the possibility
that PU.1 might participate the regulation of a B cell–spe-
cific glycosylation enzyme.
B-2 to B-1 cell conversion mediated by PU.1 loss 
The most striking effect of deleting PU.1 within the B cell
lineage is a decrease in B-2 cells and an increase in B-1 cells.
In principle, this shift can either be explained by an en-
hanced proliferation of B-1 cells, the death of B-2 cells, or
an induced reprogramming of B-2 cells into B-1 cells. Sev-
eral arguments suggest that the latter possibility is the pre-
dominant mechanism. Peritoneal B-1–like cells from knock-
out mice showed a similar proliferation capacity as the
controls, and there was no net increase in the total number
of B cells in the conditional knockout animals. (The ob-
served increased in vitro proliferation of B cell progenitors
after PU.1 ablation might be caused by the culture condi-
tions that mimic the bone marrow environment. We specu-
late that, in vivo, these cells leave the bone marrow and relo-
cate in the spleen and peritoneum, where they do not appear
to proliferate.) We also did not observe substantial cell death
induced by PU.1 deletion, supporting the finding that exci-
sion of PU.1 in CLPs does not induce a reduction of their
colony forming efficiency (33). Finally, excision of PU.1 in
ex vivo cultures of B cell precursors induced a slow down-
regulation of B220, reflecting the gradual changes observed
in vivo. These B220neg/low cells most likely do not originate
from B-1 cell precursors present in the bone marrow be-
cause a decrease of B220 expression could be detected in the
bulk of the EYFP  population already after 9 d, although se-
lection cannot be ruled out completely. Another argument
for a B-2 to B-1 cell conversion is the finding that the level
of B220 expression in the B-1–like population is highest in
the bone marrow, intermediate in the spleen, and lowest in
the peritoneum. This supports the idea that reprogramming
is initiated in bone marrow B cell precursors and completed
after the cells migrate to the spleen and peritoneum.
The observed complete loss of B-2 as well as of MZB
cells in old mice indicates that deletion of PU.1 also induces
mature B-2 cells to acquire a B-1–like phenotype. In 6-mo-
old conditional knockouts, although the EYFP B220  fol-
licular B cells are essentially unchanged, they express slightly
higher levels of CD43 and are slightly larger than their nor-
mal counterparts (Fig. 5 A and not depicted). Similarly, at
this stage MZB cells, which are thought to originate from
mature B-2 cells (12), exhibit a decrease in the expression of
CD21, possibly because they are in an early phase of the re-
programming process. In comparison with the spleen, the
shift from B-2 to B-1 cells in the peritoneum appears to oc-
cur much earlier and faster (such a shift was already seen in a
2-mo-old knockout mouse, before changes in the spleen
were apparent). Perhaps the peritoneal environment facili-
tates the conversion of B-2 to B-1 cells. 
Our proposal that the loss of PU.1 induces a B-2 to B-1
cell switch is based on the assumption that the resulting B-1
cells correspond to normal B-1 cells. Indeed, peritoneal
knockout B-1–like cells are indistinguishable from WT B-1b
cells in that they are B220neg/lowCD21lowCD23lowCD43med
IgMhigh, large in size and highly granular. However, they dif-
fer in the expression of IgD, Mac-1, and enhanced prolifera-
tion response to LPS. Together with the finding that normal
B-1 cells express much lower levels of PU.1 than B-2 cells,
this suggests that B-1 cells represent, in part, a PU.1 loss of
function phenotype. The finding that the B-1–like cells in
the knockout mice are all CD5 negative might be explained
by the possibility that low levels of PU.1 drives CD5 expres-
sion in the B-1a subset. 
Our observations support the notion that the level of
PU.1 is a decisive factor in the decision between B-1 and
B-2 cell fates. To further test this hypothesis, it will be nec-
essary to determine whether overexpression of PU.1 induces
B-1 cells to acquire a B-2 cell phenotype. The observed in-
crease in the ratio of B-1 to B-2 cells resembles that seen in
transgenic animals engineered to exhibit high levels of BCR
signaling (15). It will therefore be interesting to know
whether strong BCR signaling leads to inhibition of PU.1
expression or activity. 
MATERIALS AND METHODS
Mice. Germline-deleted PU.1 /  mice were obtained after crossing
 -actin–Cre mice (reference 34; mice provided by D. Tenen, Harvard In-
stitute of Medicine, Boston, MA) with a line in which exons 4 and 5 are
flanked by loxP sequences (PU.1 /loxP) (33). Progeny exhibiting a germline
deletion of the stop cassette were crossed with C57BL mice to remove the
 -actin–Cre transgene. The PU.1 /  mice were then crossed with each
other to obtain litters containing homozygous knockout embryos. The
strategy used to generate mice in which PU.1 is selectively inactivated in B
cells (conditional knockouts), and in which the cells with the deletion can
be tracked, is shown in Fig. S2. In short, PU.1loxP/loxP mice were crossed
with CD19-Creki/ki ROSA26-EYFPki/ki PU.1 /  mice. This generated
CD19-Cre /ki ROSA26-EYFP /ki PU.1 /loxP (conditional knockout) and
CD19-Cre /ki ROSA26-EYFP /ki PU.1 /loxP (control) mice. The genetic
background of the PU.1 germline and conditional knockout lines is a mix-
ture of C57Bl6 and 129 lines. The origin of the CD19-Creki and ROSA26-
EYFPki mice was described earlier (35). Mice were maintained in the Re-
search Animal Facility at Albert Einstein College of Medicine in accordance
with guidelines from the Institute for Animal Studies. 
Mouse genotyping. PU.1 /  and PU.1 /loxP mice were genotyped by
PCR analysis of tail DNA with the following primers: 5 -CTT CAC TGC
CCA TTC ATT GGC TCA TCA-3  (PU.1 primer 1); 5 -GCT GGG
GAC AAG GTT TGA TAA GGG AA-3  (PU.1 primer 2); and 5 -GCT
TGT GGA GTC TCC ATT AAG AAT GC-3  (PU.1 primer 3). PCR
fragments of 400- and 500-bp products of the combination of primers 1 and
2 were indicative of WT and floxed alleles, respectively. The deletion gave
rise to PCR products of 400 bp using primers 1 and 3. The oligonucleotides
used for PCR genotyping of CD19-Cre mouse and ROSA26 reporter
mouse were generated as described previously (35). The  -actin–Cre trans-
genic mice were genotyped with the Cre-specific primers 5 -CAATT-
TACTGACCGTACAC-3  and 5 -TAATCGCCATCTTCCAGCAG-3 ,JEM VOL. 202, November 21, 2005 1421
ARTICLE
which resulted in a 1-kb PCR product. All reactions were performed with
100 ng DNA for 30 cycles of 30-s denaturation at 94 C, 30-s annealing at
60 C, and 60-s elongation at 72 C. The products were analyzed on a 1.5%
agarose gel. 
Growth of fetal liver–derived B lineage cells. Fetal liver cells were
cultured on S17 stromal cells in the presence of 5 ng/ml IL-7, 10 ng/ml
SCF, and 10 ng/ml Flt-3 ligand in MEM   medium (GIBCO BRL) plus
10% FCS (Gemini Bio Products). WT B220-positive pre–B cells were iso-
lated to  95% purity from fetal liver by flow sorting and cultured as above. 
PCR analysis of heavy chain DJ and VDJ rearrangements. PCR
conditions and primers have been described in detail elsewhere (17, 36).
Amplified DNA products were analyzed on a 1.5% agarose gel and was fol-
lowed by ethidium bromide staining. PCR products were excised from the
gel, cloned, several clones were sequenced, and the reading frames of indi-
vidual sequences were determined.
Limiting dilution analysis of B cell precursors. E16.5 fetal liver cells
from two PU.1 /  embryos were pooled as well as cells from one PU.1 / 
together with two PU.1 /  embryos. LSK cells were sorted from the two
samples and 2, 5, 10, 20, 40, 80, 160, 320, 640, and 1,280 cells/well plated
in six wells each of a 96 well plate containing irradiated S17 stroma plus cy-
tokines IL-7, SCF, and Flt-3 ligand. The number of B cell colonies was
scored under the microscope between 4 and 22 d of culture. The B cell
identity of the cells in the colonies was confirmed by FACS analysis for a
limited number of the wells. 
Flow cytometry and cell sorting. 106 cells were washed once in PBS
and resuspended in 100  l of FACS buffer (4% FCS in PBS plus 0.01% so-
dium azide) containing 0.5  g of antibody. Cells were stained in the dark
on ice for 30 min. After washing, the cells were resuspended in 1 ml of
FACS buffer and analyzed by flow cytometry. CD45, B220, CD43, CD19,
BP-1, CD24, IgM, IgD, CD21, CD23, Mac-1, Gr-1, CD3, CD4, CD8,
NK1.1, and TER119 antibodies were purchased from BD Biosciences. Vi-
able cells were identified by DAPI exclusion. Cells were analyzed using
FACScalibur and LSR-II flow cytometers (Becton Dickinson) and sorted
with a MoFlo cell sorter (DakoCytomation). 
RT-PCR analysis. Total RNA was isolated and converted into cDNA as
described previously (36). All RT-PCR primers have been published (36)
except the following: PU.1 sense, 5 -CCTACATGCCCCGGATGTGC-3 
and antisense, 5 -TGCTGTCCTTCATGTCGCCG-3 ; GATA-1 sense,
5 -GACCCCCCCTTTTTTTGGAG-3  and antisense, 5 -GAGGCACA-
AGGATCTGAAGCT-3 ; pre-T  sense, 5 -CATGCTTCTCCACGA-
GTG-3  and antisense, 5 -CTATGTCCAAATTCTGTGGGTG-3 ; lck
sense, 5 -CAGAGGGCATGGCGTTCAT-3  and antisense, 5 -CTGTG-
GCTGTGAAGAAGTC-3  and ZAP-70 sense, 5 -GGAGAAGAACTT-
TGTGCACCG-3  and antisense, 5 -ATGGTGACCCCATAGCTCCA-
3 . ImageQuant software (Molecular Dynamic) was used for the quantita-
tion of PCR products.
Ablation of PU.1 with soluble TAT-Cre. CD19  cells were sorted
from the bone marrow of a PU.1 /loxP ROSA26-EYFP /ki mouse and
treated with 0.5  M TAT-Cre (provided by S. Dowdy, Howard Hughes
Medical Institute, University of California, San Diego, CA) for 1 h in
growth medium without FCS. Cells were then washed once with medium
and plated on S17 stroma cells in the presence of cytokines, IL-7, SCF, and
Flit-3L. Several days later, the cells were analyzed for successful excision of
the stop cassette of the reporter gene by monitoring EYFP expression. 
B cell proliferation assay. Peritoneal cells were obtained by flushing the
peritoneal cavity with RPMI 1640 supplemented with 10% FCS and 1 mM
EDTA. B cells were isolated in a two-step process. First, macrophages were
depleted by panning the adherent cells for 2 h at 37 C. This was followed
by FACS sorting. The B-2 cells from control mice were identified as
EYFP B220hiMac-1  and the B-1 population was EYFP B220lowMac-1low,
whereas B-1 cells from the knockouts were EYFP B220low/ . Sorted cells
(5   105 cells/well) were cultured in RPMI 1640 containing 10% FCS and
10 4 M  –mercaptoethanol in a 96-well plate without or with LPS (10 and
30  g/ml; Sigma-Aldrich). After 2 d of incubating, cells were labeled with
1  Ci [3H]TdR per well (Amersham Biosciences). 8 h later, [3H]TdR in-
corporation was measured using a   scintillation counter (PerkinElmer). All
measurements were in triplicate and the assay was repeated twice. 
Online supplemental material. Two supplemental figures are provided.
Fig. S1 shows the analysis of freshly isolated E16.5 fetal liver cells from WT
( / ), PU.1 heterozygous ( / ), and PU.1 knockout ( / ) embryos.
Fig. S2 presents a scheme that describes the breeding process by which the
B cell–specific PU.1 knockout mouse model was developed. Online sup-
plemental material is available at http://www.jem.org/cgi/content/full/
jem.20051089/DC1.
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